WallStSmart

CVS Health Corp (CVS)vsOscar Health Inc (OSCR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

CVS Health Corp generates 3317% more annual revenue ($399.83B vs $11.70B). CVS leads profitability with a 0.4% profit margin vs -3.8%. CVS earns a higher WallStSmart Score of 65/100 (C+).

CVS

Buy

65

out of 100

Grade: C+

Growth: 7.3Profit: 4.0Value: 4.7Quality: 6.5
Piotroski: 4/9Altman Z: 2.11

OSCR

Hold

45

out of 100

Grade: D

Growth: 9.3Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 3/9Altman Z: 0.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CVSSignificantly Overvalued (-18.4%)

Margin of Safety

-18.4%

Fair Value

$65.05

Current Price

$72.18

$7.13 premium

UndervaluedFair: $65.05Overvalued

Intrinsic value data unavailable for OSCR.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CVS5 strengths · Avg: 9.4/10
PEG RatioValuation
0.2110/10

Growing faster than its price suggests

Price/BookValuation
1.2x10/10

Reasonable price relative to book value

EPS GrowthGrowth
76.6%10/10

Earnings expanding 76.6% YoY

Market CapQuality
$92.62B9/10

Large-cap with strong market position

Free Cash FlowQuality
$2.61B8/10

Generating 2.6B in free cash flow

OSCR2 strengths · Avg: 8.0/10
Revenue GrowthGrowth
17.3%8/10

17.3% revenue growth

EPS GrowthGrowth
47.2%8/10

Earnings expanding 47.2% YoY

Areas to Watch

CVS4 concerns · Avg: 3.0/10
Return on EquityProfitability
2.3%3/10

ROE of 2.3% — below average capital efficiency

Profit MarginProfitability
0.4%3/10

0.4% margin — thin

Operating MarginProfitability
1.6%3/10

Operating margin of 1.6%

Debt/EquityHealth
1.243/10

Elevated debt levels

OSCR4 concerns · Avg: 2.0/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-44.4%2/10

ROE of -44.4% — below average capital efficiency

Altman Z-ScoreHealth
0.962/10

Distress zone — elevated risk

Profit MarginProfitability
-3.8%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : CVS

The strongest argument for CVS centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.21 suggests the stock is reasonably priced for its growth.

Bull Case : OSCR

The strongest argument for OSCR centers on Revenue Growth, EPS Growth. Revenue growth of 17.3% demonstrates continued momentum.

Bear Case : CVS

The primary concerns for CVS are Return on Equity, Profit Margin, Operating Margin. A P/E of 52.4x leaves little room for execution misses. Thin 0.4% margins leave little buffer for downturns.

Bear Case : OSCR

The primary concerns for OSCR are Piotroski F-Score, Return on Equity, Altman Z-Score.

Key Dynamics to Monitor

CVS profiles as a value stock while OSCR is a growth play — different risk/reward profiles.

OSCR carries more volatility with a beta of 1.90 — expect wider price swings.

OSCR is growing revenue faster at 17.3% — sustainability is the question.

CVS generates stronger free cash flow (2.6B), providing more financial flexibility.

Bottom Line

CVS scores higher overall (65/100 vs 45/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

CVS Health Corp

HEALTHCARE · HEALTHCARE PLANS · USA

CVS Health (previously CVS Corporation and CVS Caremark Corporation) is an American healthcare company that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many other brands. The company's headquarters is in Woonsocket, Rhode Island.

Visit Website →

Oscar Health Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Oscar Health, Inc. offers health insurance products and services to individuals, families, and businesses in the United States. The company is headquartered in New York, New York.

Visit Website →

Want to dig deeper into these stocks?